Page last updated: 2024-10-14
sdx 308
Description
SDX 308: a nonsteroidal anti-inflammatory agent that inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 11337099 |
SCHEMBL ID | 4798313 |
MeSH ID | M0507875 |
Synonyms (12)
Synonym |
SCHEMBL4798313 |
2-(6-bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-ethanol |
FEDANGZXMSYBKD-UHFFFAOYSA-N |
sdx 308 |
cep 18082 |
cep-18082 |
sdx-308 |
849630-44-0 |
6-bromo-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-ethanol |
2-(6-bromo-1,8-diethyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)ethanol |
Z3847488502 |
2-(6-bromo-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)ethan-1-ol |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (42.86%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (57.14%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |